John J. V. McMurray,  MD FRCP FESC FACC FAHA FRSE FMedSci British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow, United Kingdom

Benefit in Heart Failure Demonstrates Dapagliflozin – FARXIGA is Not Just a Diabetes Drug

MedicalResearch.com Interview with:

John J. V. McMurray,  MD FRCP FESC FACC FAHA FRSE FMedSci British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow, United Kingdom

Prof. McMurray

John J. V. McMurray,  MD FRCP FESC FACC FAHA FRSE FMedSci
British Heart Foundation Cardiovascular Research Centre
University of Glasgow
Glasgow, United Kingdom 

Dr. Kieran F Docherty DAPA-HF investigator British Heart Foundation Cardiovascular Research Centre, University of Glasgow

Dr. Docherty


Kieran F Docherty
DAPA-HF investigator
British Heart Foundation Cardiovascular Research Centre,
University of Glasgow

 

 


MedicalResearch.com: What is the background for this study?

Response: DAPA-HF was a double-blind randomized controlled trial comparing dapagliflozin 10 mg once daily with placebo in 4744 patients with heart failure and reduced ejection fraction (HFrEF).

The primary outcome was a composite of time to occurrence of a worsening heart failure event (principally heart failure hospitalization) or cardiovascular death, whichever came first.

Dapagliflozin reduced the primary outcome by 26% and reduced the risk of each of heart failure hospitalization and cardiovascular death individually, as well as overall mortality. Patient symptoms were also improved.

The aim of the present report was to examine the effect of dapagliflozin separately in patients with and without type 2 diabetes at baseline (45/55% split in the trial). The reason for this was that dapagliflozin was originally introduced as a glucose-lowering medication for the treatment of type 2 diabetes. We find that dapagliflozin was equally beneficial in patients with and without diabetes and was as well tolerated in patients without diabetes as in those with diabetes. More remarkably, among the patients without diabetes, dapagliflozin was as effective in participants with a completely normal glycated haemoglobin (HbA1c) as in those with prediabetes. In patients with a normal HbA1c, dapagliflozin did not lead to any reduction in HbA1c, but did improve clinical outcomes. 

MedicalResearch.com: What are the main findings?

Response: We find that dapagliflozin was equally beneficial in patients with and without diabetes and was as well tolerated in patients without diabetes as in those with diabetes.

More remarkably, among the patients without diabetes, dapagliflozin was as effective in participants with a completely normal glycated haemoglobin (HbA1c) as in those with prediabetes. In patients with a normal HbA1c, dapagliflozin did not lead to any reduction in HbA1c, but did improve clinical outcomes.

MedicalResearch.com: What should readers take away from your report? 

Response: These findings show 2 key things:

1) Dapagliflozin is not just a diabetes drug – it is clearly a treatment for HFrEF too.

2) The beneficial effect of dapagliflozin on cardiovascular outcomes is not explained by glucose lowering.

Therefore, even though dapagliflozin was originally introduced as a glucose-lowering therapy for type 2 diabetes, it clearly has a much broader therapeutic role. Indeed, it is one of the most effective treatments for heart failure that we have seen in many years. The recent news that Data Monitoring Committee recommended stopping DAPA-CKD early for efficacy supports the view that this class of drugs have wider therapeutic benefits.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: These exciting results raise the question of whether dapagliflozin might also be beneficial in the other major type of heart failure, that is heart failure with preserved ejection fraction (HFpEF). There are two large trials currently underway establishing whether SGLT2 inhibitors are effective in this other heart failure phenotype.

Disclosures: DAPA-HF was funded by AstraZeneca ,my employer, Glasgow University, was paid for my time working on the trial.

Citation:

Petrie MC, Verma S, Docherty KF, et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. Published online March 27, 2020. doi:10.1001/jama.2020.1906

JOIN OUR EMAIL LIST

We respect your privacy and will never share your details.

Apr 1, 2020 @ 4:06 pm

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.